Actively Recruiting
Validation of a Survival Prediction Score for Patients With Metastatic Cancer Receiving Palliative Radiation Therapy
Led by Indiana University · Updated on 2026-09-17
214
Participants Needed
3
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a survival prediction tool developed by Lee et al. for patients with metastatic cancer who are referred to radiation oncology for palliative treatments. This phase II clinical trial aims to validate the tools ability to predict 30-day survival by assigning a score based on objective data including laboratory values, emergency room visits, and primary cancer origin. The study categorizes patients into low-, intermediate-, and high-risk groups based on their scores. The prediction tool calculates a score from 0 to 20, where higher scores indicate a worse survival prognosis. Participants receive a score at enrollment, and their survival chances are monitored over 30, 90, and 365 days. The tool uses lab values such as white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, along with emergency room attendance and cancer type to generate the score. Participants survival and quality of life will be tracked at regular intervals using the FACIT-Pal-14 questionnaire. Researchers will assess survival rates at 30, 90, and 365 days within each risk group and evaluate patient-reported quality of life. Follow-up can be conducted virtually or by phone, and the total study duration extends up to one year after enrollment to monitor these outcomes.
CONDITIONS
Brief Title
Prospective Validation of a Points Score System Predicting 30-day Survival
Research Team
J
Jessica Anders
N
Naoyuki G Saito, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here